MTT 法作为胃癌体外化学敏感性检测的预测价值：一家机构的经验
Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution's experience.
作者信息
Wu Bin, Zhu Jin-Shui, Zhang Yi, Shen Wei-Ming, Zhang Qiang
机构信息
Department of Gastroenterology, Shanghai Sixth Hospital Affiliated to Shanghai Jiaotong University, Yishang Road 600, Shanghai 200223, China.
出版信息
World J Gastroenterol. 2008 May 21;14(19):3064-8. doi: 10.3748/wjg.14.3064.
AIM
To investigate the predictive clinical value of in vitro 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay for directing chemosensitivity in patients with gastric cancer.
METHODS
Results of a total of 353 consecutive patients with gastric cancer treated with MTT-directed chemotherapy or physician's empirical chemotherapy from July 1997 to April 2003 were reviewed and analyzed retrospectively.
RESULTS
The overall 5-year survival rate of MTT-sensitive group (MSG) and control group (CG) was 47.5% and 45.1%, respectively. The results of subgroup analysis with Cox proportional-hazards model were favorable for the MSG-sensitive group. However, no statistically significant difference in survival rate was observed between the two groups.
CONCLUSION
Individualized chemotherapy based on in vitro MTT assay is beneficial, but needs to be confirmed by further randomized controlled trials.
目的
探讨体外3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐（MTT）法对指导胃癌患者化疗敏感性的临床预测价值。
方法
回顾性分析1997年7月至2003年4月期间共353例接受MTT指导化疗或医生经验性化疗的连续性胃癌患者的结果。
结果
MTT敏感组（MSG）和对照组（CG）的总体5年生存率分别为47.5%和45.1%。Cox比例风险模型亚组分析结果对MSG敏感组有利。然而，两组之间的生存率无统计学显著差异。
结论
基于体外MTT法的个体化化疗有益，但需要进一步的随机对照试验予以证实。
Zotero 插件